[Breaking] HLB's 'Liboceranib' Receives Supplementary Request from FDA

[Breaking] HLB's 'Liboceranib' Receives Supplementary Request from FDA 원본보기 아이콘

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.